DXCM - DexCom, Inc.

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Secteur(s)Healthcare
Secteur d’activitéMedical Devices
Employés à temps plein7 500

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Kevin Ronald SayerExec. Chairman, CEO & Pres2,22MS.O.1958
Mr. Jereme M. SylvainExec. VP, CFO & Chief Accounting Officer841,14kS.O.1980
Mr. Jacob Steven LeachExec. VP & COO994,13kS.O.1978
Mr. Girish NaganathanExec. VP & CTO423,92kS.O.1977
Mr. Michael Jon BrownExec. VP & Chief Legal Officer954,46kS.O.1970
Mr. Shelly Ramasamy SelvarajSr. VP & Chief Information OfficerS.O.S.O.1959
Mr. Sean ChristensenDirector of Corp. Affairs & Head of Investor RelationsS.O.S.O.S.O.
Mr. Matthew DolanExec. VP of Strategy, Corp. Devel. & Dexcom LabsS.O.S.O.1981
Ms. Sadie M. SternExec. VP & Chief HR OfficerS.O.S.O.1975
Mr. Andrew K. BaloExec. VP of Global Medical Affairs, Access & EvidenceS.O.S.O.1948
Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de DexCom, Inc. en date du 1 juin 2023 est 4. Les scores principaux sont Audit : 1; Société : 9; Droits des actionnaires : 6; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.